Now May Be the Big Moment for These 2 COVID Stocks
When most of us think of successful coronavirus stocks, we think of vaccine makers. But treatment makers are gaining momentum these days -- and that movement may not be over. Why? Coronavirus cases have been climbing since July. Many cases strike unvaccinated individuals. But even some vaccinated people have experienced breakthrough infections.
As a result, demand has surged for a particular treatment that wasn't always so popular: monoclonal antibodies. And states hardest hit by the crisis, such as Florida, have raced to open new treatment centers. In July, the government shipped five times more antibody treatments to states than it did in the previous month. Now, this may be the big moment for two makers of monoclonal antibodies -- and it's likely to lead to more revenue in the future too. Let's take a closer look.
Image source: Getty Images.
Source Fool.com
